SCHEMBL5775261

SCHEMBL5775261

CCCCS(=O)(=O)c1cc(OC)cc(F)c1C(=O)O

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGES O14684 1/20 0.43
CCNB2 O95067 1/20 0.39
CCNE2 O96020 1/20 0.39
CDK1 P06493 1/20 0.39
CDK4 P11802 1/20 0.39
CCNB1 P14635 1/20 0.39
CCND1 P24385 1/20 0.39
CCNE1 P24864 1/20 0.39
CDK2 P24941 1/20 0.39
CCND2 P30279 1/20 0.39
CCND3 P30281 1/20 0.39
CCNB3 Q8WWL7 1/20 0.39
KDM4E B2RXH2 2/20 0.38
HSD17B10 Q99714 1/20 0.38
PTGS2 P35354 1/20 0.35
FFAR1 O14842 1/20 0.35
FFAR4 Q5NUL3 1/20 0.35
BMP1 P13497 2/20 0.35
MEP1B Q16820 1/20 0.35
HTT P42858 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5776178 0.86 CCNB2 (0.36) PTGESCCNB2CCNE2CDK1CDK4
SCHEMBL5774733 0.81 CYP24A1 (0.36) CCNB2CCNE2CDK1CDK4CCNB1
SCHEMBL1646977 0.75 POLB (0.45) KDM4EPTGS2HTTMAPTTSHR
SCHEMBL5104447 0.70 PLA2G2A (0.54) CCNB2CCNE2CDK1CDK4CCNB1
SCHEMBL20314696 0.70 L3MBTL1 (0.54) HTTMAPTTSHRSOAT1
SCHEMBL23389812 0.70 KMT2A (0.55) KDM4EHSD17B10HTTTP53CYP3A4
SCHEMBL7195213 0.70 POLB (0.55) PTGESKDM4EHSD17B10TP53CYP3A4
SCHEMBL18170324 0.70 MAPK1 (0.51) KDM4EHSD17B10PTGS2HTTTP53
SCHEMBL21995828 0.68 TAAR1 (0.42) CDK4CDK2KDM4EMEP1BHTT
SCHEMBL28453775 0.68 GPR35 (0.41) KDM4EHTTMAPTTSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1483257-B1 QUINAZOLINE COMPOUNDS USEFUL IN THERAPY PFIZER LTD (GB) 2006-09-13 EP disclosed
US-6936619-B2 Cardiovascular disorders; antilipemic agents; sexual disorders PFIZER, INC. (US) 2005-08-30 US disclosed
EP-1483257-A1 QUINAZOLINE COMPOUNDS USEFUL IN THERAPY Pfizer Limited (GB) 2004-12-08 EP disclosed
US-20040029859-A1 Compounds useful in therapy PFIZER INC. 2004-02-12 US disclosed
WO-2003076427-A1 QUINAZOLINE COMPOUNDS USEFUL IN THERAPY PFIZER LIMITED (GB) 2003-09-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040029859-A1 Compounds useful in therapy ADRA1D, HSD3B1, PTGER1 PTGES 194/4885CCNB2 3287/4885CCNE2 1253/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.